论文部分内容阅读
目的研究miRNAs在乳腺癌患者血清中的异常表达及其作为潜在诊断标志物的价值。方法将乳腺癌患者纳入观察组,并分为TNMⅠ、TNMⅡ、TNMⅢ、TNMⅣ期,选择乳腺活检阴性患者作为对照组,采集血清检测MicroRNAS(简称miRNAS)含量。结果观察组患者miR-339、miR-21、miR-155、miR-103的含量高于对照组的,呈现出TNMⅠTNMⅡ>TNMⅢ>TNMⅣ期,且与TNM分期呈负相关。结论乳腺癌组织中miRNA的表达量存在异常,TNM分期越差,miR-339、miR-21、miR-155、miR-103的含量越高,miR-45、miR-96、miR-129的含量越低,可作为乳腺癌的诊断标志物。
Objective To investigate the abnormal expression of miRNAs in the serum of breast cancer patients and its value as a potential diagnostic marker. Methods The patients with breast cancer were included in the observation group. The patients were divided into TNMⅠ, TNMⅡ, TNMⅢ and TNMⅣ. The patients with negative breast biopsy were selected as the control group, and the serum samples were collected for the detection of MicroRNAS (referred to as miRNAS). Results The levels of miR-339, miR-21, miR-155 and miR-103 in the observation group were significantly higher than those in the control group, showing TNMⅠ TNMⅡ> TNMⅢ> TNMⅣ, and negatively correlated with TNM stage. Conclusion The expression of miRNA in breast cancer tissues is abnormal. The worse the TNM stage, the higher the content of miR-339, miR-21, miR-155 and miR-103, The lower, can be used as a diagnostic marker for breast cancer.